395 related articles for article (PubMed ID: 29038000)
1. Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer.
Mekala JR; Naushad SM; Ponnusamy L; Arivazhagan G; Sakthiprasad V; Pal-Bhadra M
Gene; 2018 Jan; 641():248-258. PubMed ID: 29038000
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
Ramaiah MJ; Tangutur AD; Manyam RR
Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
[TBL] [Abstract][Full Text] [Related]
5. Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.
Maiti A; Qi Q; Peng X; Yan L; Takabe K; Hait NC
Int J Oncol; 2019 Jul; 55(1):116-130. PubMed ID: 31059004
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises.
Garmpis N; Damaskos C; Garmpi A; Kalampokas E; Kalampokas T; Spartalis E; Daskalopoulou A; Valsami S; Kontos M; Nonni A; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Cancer Genomics Proteomics; 2017; 14(5):299-313. PubMed ID: 28870998
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
Zhang K; Liu Z; Yao Y; Qiu Y; Li F; Chen D; Hamilton DJ; Li Z; Jiang S
J Med Chem; 2021 Apr; 64(7):4020-4033. PubMed ID: 33745280
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment.
Zhou L; Yu CW
Pharmacol Res; 2024 Jun; 204():107205. PubMed ID: 38719195
[TBL] [Abstract][Full Text] [Related]
10. Epi-drugs as triple-negative breast cancer treatment.
Idrissou M; Sanchez A; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
Epigenomics; 2020 Apr; 12(8):725-742. PubMed ID: 32396394
[TBL] [Abstract][Full Text] [Related]
11. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
[TBL] [Abstract][Full Text] [Related]
12. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors increase microRNA-146a expression and enhance negative regulation of interleukin-1β signaling in osteoarthritis fibroblast-like synoviocytes.
Wang JH; Shih KS; Wu YW; Wang AW; Yang CR
Osteoarthritis Cartilage; 2013 Dec; 21(12):1987-96. PubMed ID: 24107356
[TBL] [Abstract][Full Text] [Related]
15. Marine Actinomycetes as potential source for histone deacetylase inhibitors and epigenetic modulation.
Varghese TA; Jayasri MA; Suthindhiran K
Lett Appl Microbiol; 2015 Jul; 61(1):69-76. PubMed ID: 25880615
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase Inhibitors in Cancer Therapy.
Sun Y; Sun Y; Yue S; Wang Y; Lu F
Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
[TBL] [Abstract][Full Text] [Related]
17. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
Lai TH; Ewald B; Zecevic A; Liu C; Sulda M; Papaioannou D; Garzon R; Blachly JS; Plunkett W; Sampath D
Clin Cancer Res; 2016 Jul; 22(14):3537-49. PubMed ID: 26858310
[TBL] [Abstract][Full Text] [Related]
18. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
Bai Y; Ahmad D; Wang T; Cui G; Li W
Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibition regulates miR-449a levels in skeletal muscle cells.
Poddar S; Kesharwani D; Datta M
Epigenetics; 2016 Aug; 11(8):579-87. PubMed ID: 27184529
[TBL] [Abstract][Full Text] [Related]
20. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
